Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8856832 | 0.80 | — | — | |
| SCHEMBL7792035 | 0.71 | — | — | |
| SCHEMBL7792038 | 0.71 | — | — | |
| SCHEMBL2245946 | 0.69 | LMNA (0.45) | LMNA | |
| SCHEMBL9642528 | 0.69 | LMNA (0.38) | LMNA | |
| SCHEMBL2245952 | 0.69 | LMNA (0.45) | LMNA | |
| SCHEMBL17439644 | 0.68 | — | — | |
| Acrylic Acid SCHEMBL28528850 | 0.67 | LMNA (0.43) | LMNA | |
| Oxalic Acid SCHEMBL11832408 | 0.66 | ALDH1A1 (0.60) | LMNA | |
| SCHEMBL326495 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707550-B2 | Polyphosphate-functionalized inorganic nanoparticles as hemostatic compositions and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-25 | — | — | US | claimed |
| US-20210213159-A1 | Polyphosphate-Functionalized Inorganic Nanoparticles as Hemostatic Compositions and Methods of Use | THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2021-07-15 | — | — | US | claimed |
| EP-1626749-B1 | IMPLANTS COMPRISING FUNCTIONALIZED CARBON SURFACES | CINV AG (DE) | 2008-10-08 | — | — | EP | claimed |
| US-20240157022-A1 | Polyphosphate-Functionalized Inorganic Nanoparticles as Hemostatic Compositions and Methods of Use | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2024-05-16 | — | — | US | disclosed |
| EP-4360656-A2 | POLYPHOSPHATE-FUNCTIONALIZED INORGANIC NANOPARTICLES AS HEMOSTATIC COMPOSITIONS AND METHODS OF USE | The Regents of The University of California (US) | 2024-05-01 | — | — | EP | disclosed |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | disclosed |
| EP-3659627-B1 | POLYPHOSPHATE-FUNCTIONALIZED INORGANIC NANOPARTICLES AS HEMOSTATIC COMPOSITIONS AND METHODS OF USE | UNIV CALIFORNIA (US) | 2024-02-14 | — | — | EP | disclosed |
| US-11707550-B2 | Polyphosphate-functionalized inorganic nanoparticles as hemostatic compositions and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-25 | — | — | US | disclosed |
| US-20210213159-A1 | Polyphosphate-Functionalized Inorganic Nanoparticles as Hemostatic Compositions and Methods of Use | THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2021-07-15 | — | — | US | disclosed |
| US-20210138069-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2021-05-13 | — | — | US | disclosed |
| US-10842908-B2 | Polyphosphate-functionalized inorganic nanoparticles as hemostatic compositions and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-11-24 | — | — | US | disclosed |
| US-20080166417-A1 | Preventing intraocular pressurization; incorporating steroid as fine particles in ophthalmic formulation | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| WO-2008006235-A2 | SCFV ANTIBODIES WHICH PASS EPITHELIAL AND/OR ENDOTHELIAL LAYERS | ESBATECH AG (CH) | 2008-01-17 | — | — | WO | disclosed |
| EP-1867334-A1 | METHOD OF RELIEVING OR AVOIDING SIDE EFFECT OF STEROID COMPOUND | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-12-19 | — | — | EP | disclosed |
| EP-1830902-A2 | COMBINATION COMPRISING AN AGENT PROVIDING A SIGNAL, AN IMPLANT MATERIAL AND A DRUG | CINVENTION AG (DE) | 2007-09-12 | — | — | EP | disclosed |
| CN-1829667-A | Method for the production of porous carbon-based molded bodies, and use thereof as cell culture carrier systems and culture systems | BLUE MEMBRANES GMBH (DE) | 2006-09-06 | — | — | CN | disclosed |
| US-20060177379-A1 | Composition comprising an agent providing a signal, an implant material and a drug | CINVENTION AG (DE) | 2006-08-10 | — | — | US | disclosed |
| WO-2006069677-A2 | COMBINATION COMPRISING AN AGENT PROVIDING A SIGNAL, AN IMPLANT MATERIAL AND A DRUG | CINVENTION AG (DE) | 2006-07-06 | — | — | WO | disclosed |
| US-20050089545-A1 | Drug delivery system for the subconjunctival administration of fine grains | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1484054-A1 | DRUG DELIVERY SYSTEM FOR THE SUBCONJUNCTIVAL ADMINISTRATION OF FINE GRAINS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210138069-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | CETP, LIPA, APOB | LMNA 1183/4885 |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | LMNA 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.